Antibe Therapeutics
Jump to navigation
Jump to search
"Antibe Therapeutics (“Antibe”) is a public biotech company with a drug platform of game-changing therapeutics in pain and inflammation. Its lead drug, ATB-346, recently showed unequivocal superiority to naproxen in GI safety, and its combined pipeline is targeting a global market opportunity in excess of $20 billion." [1]
Contents
Scientific Advisory Board [2]
- Louis J. Ignarro, Andre Buret, Daniel K. Podolsky, Giuseppe Cirino, Peter B. Ernst, Richard H. Hunt, Jane A. Mitchell, William Sessa, Gilberto de Nucci, Philip M. Sherman, Derek Gilroy
Resources and articles
Related Sourcewatch
References
- ↑ Antibe Therapeutics About, organizational web page, accessed August 15, 2018.
- ↑ Antibe cientific-advisory-board, organizational web page, accessed August 15, 2018.
